Conditional survival rates vary across stage categories in patients with nonmetastatic intrahepatic cholangiocarcinoma following surgery, according to a new study published in the Scandinavian Journal of Gastroenterology.

This finding is important as it has implications in individualized clinical counseling and decision‐making for the disease.

To examine the conditional survival rates of patients with nonmetastatic intrahepatic cholangiocarcinoma following surgical treatment according to disease stage, a team of researchers from Fudan University Shanghai Cancer Center in China conducted a study on 608 patients with the disease.

Continue Reading

Conditional survival is defined as the probability of surviving a certain number of years further, given that a patient has already survived a number of years after diagnosis. Of the 608 patients, 109 had pT1aN0, 96 had pT1bN0, 205 had pT2N0, 82 had pT3-5N0, and 116 had pTanyN1.

Read more about cholangiocarcinoma treatment

The researchers calculated that in patients with pT1b, pT2, pT3-4N0, and pTanyN1, conditional cancer-specific mortality-free estimates increased to 87%, 70%, 86%, and 54% from 75%, 66%, 53%, and 36%, respectively, after 3 years follow-up that was event-free.

In patients with pT1aN0, the conditional cancer-specific mortality-free estimate decreased from 87% to 79%. Statistical analyses showed that patients with pT2N0, pT3-4N0, and pTanyN1-3 had higher cancer-specific mortality rates compared to patients with pT1aN0.

Considering the accessibility of tumor, nodes, and metastases staging, conducting postoperative consultation is important, the researchers said. This can help patients make informed decisions about their work and personal lives.

Intrahepatic cholangiocarcinoma is the second most common form of hepatic cancer, the mortality of which has been increasing. For patients with nonmetastatic disease, the only curative option is a hepatectomy. However, the survival rates after hepatectomy are still low with postoperative 5-year survival rates of 30% to 40%.


Yan X, Wang L, Meng Z. Conditional cancer-specific survival after radical hepatectomy in patients with nonmetastatic intrahepatic cholangiocarcinoma. Scand J Gastroenterol. Published online January 10, 2022. doi:10.1080/00365521.2021.2022192